Researchers from Charité – Universitätsmedizin Berlin and the Zuse Institute Berlin have developed a new generation of pain medications.
The researchers used computer simulations to develop new opioids that will only work at sites affected by injury or inflammation. These drugs can prevent the occurrence of brain- and gut-related side effects typically associated with conventional opioids and have been shown to be successful in preclinical studies. Results from this research have been published in Pain* and Scientific Reports**.
Opioids are a class of drugs with powerful pain-relieving properties. They are mainly used to treat the pain associated with tissue damage and inflammation, such as that caused by surgery or cancer. Common side effects associated with their use include drowsiness, nausea, constipation, dependency and, in some cases, respiratory arrest. The research team, which is led by Prof. Dr. Christoph Stein of the Department of Anesthesiology and Surgical Intensive Care Medicine on Campus Benjamin Franklin, are hoping to develop new types of pain medications which will work without producing dangerous side effects. Collaborating with PD Dr. Marcus Weber of the Zuse Institute Berlin, the researchers used computer simulations to develop two new opioids. In both cases, the researchers used fentanyl as the starting molecule.
The researchers hypothesized that tissues which are damaged or inflamed show stronger interaction between ‘opioid agonists’ – the substances that elicit the pain-relieving effect – and the opioid receptors they bind to. Their computer simulations suggested that this is due to an increased concentration of protons in inflamed tissues, which leads to lower pH values than in healthy tissues, resulting in acidic conditions. Opioid molecules need to undergo protonation before they can bind to and activate opioid receptors. The researchers used this knowledge to design two drugs that would only exist in their protonated state in the presence of inflammation. This restricts opioid receptor activation to sites of tissue damage or inflammation, rather than receptors in the brain or gut.
“Our innovative design method provides a robust basis for a new generation of pain medications,” reports Prof. Stein. He adds: “These drugs could help us both to avoid the dangerous side effects of conventional opioids and to reduce complications. They would also help us stem the opioid crisis, a problem that is particularly evident in the United States.”
The researchers hope to further develop these newly-designed drugs in order to make them available to patients. They also plan to enhance their understanding of the molecular processes underlying the complex interactions seen in inflamed tissues, in the hope that they may be able to support opioid optimization through the insights they gain. Ideally, their insights will also be beneficial for other drugs, such as those used to treat high blood pressure.
The Latest on: Pain medications
via Google News
The Latest on: Pain medications
- Explore a few alternative ways to alleviate chronic painon November 28, 2020 at 4:00 am
According to the Centers for Disease Control and Prevention, an estimated 20.4% of U.S. adults had chronic pain, and 8% percent of U.S. adults had high-impact chronic pain in 2016.
- $150+ Billion Chronic Pain Treatment Market - Global Industry Analysis and Growth Forecast to 2030 - ResearchAndMarkets.comon November 27, 2020 at 9:32 am
By Product, Indication, Application, Distribution Channel, End User - Global Industry Analysis and Growth Forecast to ...
- Pain Management Drugs and Devices Market Steady Growth to Be Witnessed by 2021 to 2030|| Abbvie Inc., Astrazeneca Depomed Inc., Djo Global Inc.on November 26, 2020 at 2:57 am
Prudour Pvt. Ltd :The Core Objective of Pain Management Drugs and Devices Market [Update 2021] reports gives a far-reaching review of the worldwide market size and global trends with values. This ...
- LATAM Pain Management Drugs Market to Garner $3.38 Billion by 2027: Allied Market Researchon November 25, 2020 at 8:18 am
As per the report published by Allied Market Research, the LATAM Pain Management Drugs Market was pegged at $2.68 billion in 2019, and is projected to reach $3.38 billion by 2027, growing at a CAGR of ...
- Global Chronic Pain Treatment Market Analysis and Growth Forecast Report 2020-2030on November 25, 2020 at 12:43 am
The "Chronic Pain Treatment Market Research Report: By Product, Indication, Application, Distribution Channel, End User - Global Industry Analysis and Growth Forecast to 2030" report has been added to ...
- Global Osteoarthritis Pain Drugs Market 2020: Industry Size, Outlook, Share, Demand, Manufacturers and 2024 Forecast Research’son November 23, 2020 at 2:08 am
Global “Osteoarthritis Pain Drugs" Market 2024 Research Report provide in-depth study of the present state of the ...
- Global Conventional and Alternative Pain Treatment Markets Report 2020-2025on November 19, 2020 at 10:58 pm
The "Conventional and Alternative Pain Treatment Markets" report has been added to ResearchAndMarkets.com's offering. This report is designed to be a helpful business tool that will provide a thorough ...
- Patients pay thousands for back pain treatment — with little scientific evidence that it workson November 19, 2020 at 7:44 am
Claims of success for spinal decompression devices stretch the truth, an investigation found. The treatment hasn't been proven in rigorous studies.
- SAM by ZetrOZ is the New, Go-To, Cost-Effective Treatment for Knee Arthritis Painon November 17, 2020 at 10:20 pm
ZetrOZ Systems, developers of Sustained Acoustic Medicine (SAM), a wearable, home-use, FDA-cleared bio regenerative medical device, announces that its product has been recognized as a cost-effective ...
via Bing News